Gout therapeutics: new drugs for an old disease (Q37780849)

23 August 2017

Gout therapeutics: new drugs for an old disease (English)

1 reference

23 August 2017

Christopher M Burns

1

1 reference

PubMed ID

20719377

23 August 2017

Robert L Wortmann

series ordinal

2

1 reference

PubMed ID

20719377

23 August 2017

language of work or name

English

0 references

publication date

16 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

377

1 reference

23 August 2017

9760

1 reference

23 August 2017

165-177

1 reference

Identification of urate crystals in gouty synovial fluid

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Epidemiology, risk factors, and lifestyle modifications for gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

The changing epidemiology of gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Validity of gout diagnoses in administrative data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

1 reference

7 January 2021

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Urate oxidase: primary structure and evolutionary implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

High-level production of a peroxisomal enzyme: Aspergillus flavus uricase accumulates intracellularly and is active in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Management of hyperuricemia with rasburicase review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Resolution of gouty tophi after twelve weeks of pegloticase treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

New standards for uric acid excretion and evidence for an inducible transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Molecular identification of a renal urate anion exchanger that regulates blood urate levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Urate transport across the apical membrane of renal proximal tubules

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Human renal organic anion transporter 4 operates as an asymmetric urate transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

SLC2A9 is a high-capacity urate transporter in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous Gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Gout-associated uric acid crystals activate the NALP3 inflammasome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

A pilot study of IL-1 inhibition by anakinra in acute gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

The inflammatory process of gout and its treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Gout. Novel therapies for treatment of gout and hyperuricemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

The optimal use of allopurinol: an audit of allopurinol use in South Auckland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Gout: can management be improved?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Gout medication treatment patterns and adherence to standards of care from a managed care perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Serum urate levels and gout flares: analysis from managed care data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

We can make gout management more successful now.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Gout management: let's get it right this time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960665-4

7 January 2021

10.1016/S0140-6736(10)60665-4

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20719377